Methylphenidate-induced acute orofacial and extremity dyskinesia

Area of Science:

• Neuroscience
• Pharmacology
• Pediatrics

Background:

• Methylphenidate is a common stimulant medication for Attention-Deficit/Hyperactivity Disorder (ADHD).
• Sodium valproate is an anticonvulsant medication used for epilepsy.
• Dyskinesia is a movement disorder characterized by involuntary muscle contractions.

Observation:

• A 7-year-old male patient developed orofacial and limb dyskinesia after his initial dose of methylphenidate.
• The patient was concurrently undergoing treatment with sodium valproate for epilepsy.
• Orofacial dyskinesia emerged 5 hours post-administration, resolving within 48 hours.

Findings:

• This case represents the second reported instance of both orofacial and limb dyskinesia occurring acutely after the first methylphenidate dose.
• Limb dyskinesia is a known side effect, but concurrent orofacial dyskinesia is rare.
• The event underscores potential individual variations in drug response and sensitivity.

Implications:

• Highlights the importance of monitoring for rare but significant adverse drug reactions to methylphenidate.
• Suggests complex drug-receptor interactions may influence methylphenidate's side effect profile.
• Emphasizes the need for personalized treatment approaches considering potential individual sensitivities.